Vaccination issues in patients with chronic kidney disease

Expert Review of Vaccines

Volumn 13, Issue 2, 2014, Pages 285-298

  Mathew, Roy ^a   Mason, Darius ^b   Kennedy, Jeffrey S ^c  

^a STRATTON VA MEDICAL CENTER   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c ALBANY MEDICAL CENTER   (United States)

Author keywords

antibody; chronic kidney disease; end stage renal disease; immunity; infection; prevention; T cell; vaccination

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; LIVE VACCINE; PNEUMOCOCCUS VACCINE; STAPHYLOCOCCUS VACCINE; VACCINE; VARICELLA ZOSTER VACCINE;

ADULT DISEASE; CHRONIC KIDNEY DISEASE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; INFLUENZA VACCINATION; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; TETANUS; VACCINATION;

COMMUNICABLE DISEASES; HUMANS; RENAL INSUFFICIENCY, CHRONIC; VACCINATION; VACCINES;

EID: 84893029200     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.874950     Document Type: Review

References (107)

1. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351(13):1296-305
2. U.S.Renal Data System. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD, USA 2012
3. Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end-stage renal disease. Chest 2001;120(6):1883-7
4. Naqvi SB, Collins AJ. Infectious complications in chronic kidney disease. Adv Chronic Kidney Dis 2006;13(3):199-204
5. Gilbertson DT, Unruh M, Mcbean AM, et al. Influenza vaccine delivery and effectiveness in end-stage renal disease. Kidney Int 2003;63(2):738-43
6. Bond TC, Spaulding AC, Krisher J, Mcclellan W. Mortality of dialysis patients according to influenza and pneumococcal vaccination status. Am J Kidney Dis 2012; 60(6):959-65
7. Hauser AB, Stinghen AE, Kato S, et al. Characteristics and causes of immune dysfunction related to uremia and dialysis. Perit Dial Int 2008;28(Suppl 3):S183-7
8. Silverstein DM. Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol 2009;24(8):1445-52
9. Pesanti EL. Immunologic defects and vaccination in patients with chronic renal failure. Infect Dis Clin North Am 2001; 15(3):813-32
10. Girndt M, Sester M, Sester U, et al. Molecular aspects of T-and B-cell function in uremia. Kidney Int Suppl 2001;78: S206-11
11. Descamps-Latscha B, Chatenoud L. T cells and B cells in chronic renal failure. Semin Nephrol 1996;16(3):183-91
12. Zheng G, Wang Y, Mahajan D, et al. The role of tubulointerstitial inflammation. Kidney Int Suppl 2005(94):S96-100
13. Kato S, Chmielewski M, Honda H, et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 2008; 3(5):1526-33.
14. Group KDIGOKCW. KDIGO. 2012 clinical practice guideline for the evaluation and management of Chronic kidney disease. Kidney Int Suppl 2013;3: 1-150.
15. Daroza G, Loewen A, Djurdjev O, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis 2003;42(6):1184-92
16. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010;33(4):492-503.
17. Vaziri ND, Pahl MV, Crum A, Norris K. Effect of uremia on structure and function of immune system. J Ren Nutr 2012;22(1): 149-56
18. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005; 11(4 Suppl):S63-8
19. Verkade MA, Van Druningen CJ, Vaessen LM, et al. Functional impairment of monocyte-derived dendritic cells in patients with severe chronic kidney disease. Nephrol Dial Transplant 2007;22(1):128-38
20. Hesselink DA, Betjes MG, Verkade MA, et al. The effects of chronic kidney disease and renal replacement therapy on circulating dendritic cells. Nephrol Dial Transplant 2005;20(9):1868-73
21. Chen LY, Lin YL, Chiang BL. Levamisole enhances immune response by affecting the activation and maturation of human monocyte-derived dendritic cells. Clin Exp Immunol 2008;151(1):174-81
22. Zhang W, Du X, Zhao G, et al. Levamisole is a potential facilitator for the activation of Th1 responses of the subunit HBV vaccination. Vaccine 2009;27(36):4938-46
23. Kang Y, Jin H, Zheng G, et al. The adjuvant effect of levamisole on killed viral vaccines. Vaccine 2005;23(48-49):5543-50
24. Cruz LJ, Tacken PJ, Rueda F, et al. Targeting nanoparticles to dendritic cells for immunotherapy. Methods Enzymol 2012;509:143-63
25. Zhang D, Xia Q, Wu J, et al. Construction and immunogenicity of DNA vaccines encoding fusion protein of murine complement C3d-p28 and GP5 gene of porcine reproductive and respiratory syndrome virus. Vaccine 2011;29(4):629-35
26. Kamimura D, Bevan MJ. Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo. J Exp Med 2007;204(8):1803-12
27. Bitsaktsis C, Iglesias BV, Li Y, et al. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcgamma receptor type I protects against pneumococcal infection through complement-and lactoferrin-mediated bactericidal activity. Infect Immun 2012; 80(3):1166-80
28. Litjens NH, Huisman M, Van Den Dorpel M, Betjes MG. Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients. J Am Soc Nephrol 2008;19(8): 1483-90 . One of the most prominent groups in the field of immune deficits associated with chronic kidney disease. Very eloquent well thought out experiments exploring T cell deficits as it relates to vaccine response.
29. Litjens NH, Van Druningen CJ, Betjes MG. Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. Clin Immunol 2006; 118(1):83-91
30. Krishnamurthy G, Kher V, Naik S. Low response to HBsAg vaccine in chronic renal failure patients is not due to intrinsic defect of B cells. Scand J Urol Nephrol 2002; 36(5):377-82
31. Contin C, Pitard V, Delmas Y, et al. Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients. Immunology 2003;110(1): 131-40
32. Kim KW, Chung BH, Jeon EJ, et al. B cell-associated immune profiles in patients with end-stage renal disease (ESRD). Exp Mol Med 2012;44(8):465-72
33. Burdick RA, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2003;63(6):2222-9
34. Centers-for-Disease-Control-and-Prevention. A comprehensive immunization strategy to elminate transmission fo hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR 2006;55(No. RR-16):2-33
35. Wasley A, Kruszon-Moran D, Kuhnert W, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 2010;202(2): 192-201
36. Fabrizi F, Messa P, Martin P. Hepatitis B virus infection and the dialysis patient. Semin Dial 2008;21(5):440-6
37. Schroth RJ, Hitchon CA, Uhanova J, et al. Hepatitis B vaccination for patients with chronic renal failure. Cochrane Database Syst Rev 2004;(3):CD003775
38. Edey M, Barraclough K, Johnson DW. Review article: hepatitis B and dialysis. Nephrology (Carlton) 2010;15(2):137-45
39. Ghadiani MH, Besharati S, Mousavinasab N, Jalalzadeh M. Response rates to HB vaccine in CKD stages 3-4 and hemodialysis patients. J Res Med Sci 2012; 17(6):527-33
40. El-Reshaid K, Al-Mufti S, Johny KV, Sugathan TN. Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients. Vaccine 1994;12(3):223-34
41. Fabrizi F, Dixit V, Magnini M, et al. Metaanalysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment Pharmacol Ther 2006;24(3): 497-506
42. Lewis-Ximenez LL, Oliveira JM, Mercadante LA, et al. Serological and vaccination profile of hemodialysis patients during an outbreak of hepatitis B virus infection. Nephron 2001;87(1):19-26.
43. Weinstein T, Chagnac A, Boaz M, et al. Improved immunogenicity of a novel third-generation recombinant hepatitis B vaccine in patients with end-stage renal disease. Nephron Clin Pract 2004;97(2): c67-72
44. Brown CM, Donlon S, O'kelly P, et al. A prospective study of hepatitis B vaccination -a comparison of responders versus nonresponders. Ren Fail 2011;33(3): 276-9
45. Verkade MA, Van De Wetering J, Klepper M, et al. Peripheral blood dendritic cells and GM-CSF as an adjuvant for hepatitis B vaccination in hemodialysis patients. Kidney Int 2004;66(2):614-21
46. Singh NP, Mandal SK, Thakur A, et al. Efficacy of GM-CSF as an adjuvant to hepatitis B vaccination in patients with chronic renal failure-results of a prospective, randomized trial. Ren Fail 2003;25(2): 255-66
47. Fabrizi F, Ganeshan SV, Dixit V, Martin P. Meta-analysis: the adjuvant role of granulocyte macrophage-colony stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease. Aliment Pharmacol Ther 2006; 24(5):789-96
48. Alavian SM, Tabatabaei SV. Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials. Clin Ther 2010;32(1): 1-10
49. Fabrizi F, Dixit V, Messa P, Martin P. Meta-analysis: levamisole improves the immune response to hepatitis B vaccine in dialysis patients. Aliment Pharmacol Ther 2010;32(6):756-62
50. Halperin SA, Ward B, Cooper C, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. Vaccine 2012; 30(15). 2556-63
51. Halperin SA, Mcneil S, Langley JM, et al. Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults. Vaccine 2012;30(36):5445-8
52. Sablan BP, Kim DJ, Barzaga NG, et al. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine 2012;30(16):2689-96
53. Janssen RS, Mangoo-Karim R, Pergola PE, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease. Vaccine 2013;31(46): 5306-13
54. Niu MT, Polish LB, Robertson BH, et al. Multistate outbreak of hepatitis A associated with frozen strawberries. J Infect Dis 1992; 166(3):518-24
55. Craig AS, Watson B, Zink TK, et al. Hepatitis A outbreak activity in the United States: responding to a vaccine-preventable disease. Am J Med Sci 2007;334(3):180-3
56. Glikson M, Galun E, Oren R, et al. Relapsing hepatitis A. Review of 14 cases and literature survey. Medicine (Baltimore) 1992;71(1):14-23
57. Krugman S, Ward R, Giles JP. The natural history of infectious hepatitis. Am J Med 1962;32:717-28
58. Choi HK, Song YG, Han SH, et al. Clinical features and outcomes of acute kidney injury among patients with acute hepatitis A. J Clin Virol 2011;52(3): 192-7
59. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994;271(17): 1328-34
60. Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992;327(7):453-7
61. Ajmera V, Xia G, Vaughan G, et al. What factors determine the severity of hepatitis A-related acute liver failure? J Viral Hepat 2011;18(7):e167-74
62. Tilzey AJ, Palmer SJ, Barrow S, et al. Effect of Hepatitis A vaccination schedules on immune response. Vaccine 1992; 10(Suppl 1):S121-3
63. Tung J, Carlisle E, Smieja M, et al. A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients. Am J Kidney Dis 2010;56(4):713-19
64. Fleischmann EH, Kruppenbacher J, Bock HL, Weber M. Active immunization against hepatitis A in dialysis patients. Nephrol Dial Transplant 2002;17(10): 1825-8
65. Green MS, Cohen D, Lerman Y, et al. Depression of the immune response to an inactivated hepatitis A vaccine administered concomitantly with immune globulin. J Infect Dis 1993;168(3):740-3
66. Kuramoto I, Fujiyama S, Matsushita K, Sato T. Immune response after hepatitis A vaccination in haemodialysis patients: comparison with hepatitis B vaccination. J Gastroenterol Hepatol 1994;9(3):228-31
67. Dushoff J, Plotkin JB, Viboud C, et al. Mortality due to influenza in the United States -an annualized regression approach using multiple-cause mortality data. Am J Epidemiol 2006;163(2):181-7
68. Nikoskelainen J, Vaananed P, Forsstrom J, Kasanen A. Influenza Vaccination in patients with chronic renal failure. Scand J Infect Dis 1982;14(4):245-51
69. Quintana LF, Serra N, De Molina-Llaurado P, et al. Influence of renal replacement therapy on immune response after one and two doses of the A (H1N1) pdm09 vaccine. Influenza Other Respi Viruses 2013;7(5):809-14
70. Broeders NE, Hombrouck A, Lemy A, et al. Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. Clin J Am Soc Nephrol 2011;6(11):2573-8
71. Antonen JA, Pyhala R, Hannula PM, et al. Influenza vaccination of dialysis patients: cross-reactivity of induced haemagglutination-inhibiting antibodies to H3N2 subtype antigenic variants is comparable with the response of naturally infected young healthy adults. Nephrol Dial Transplant 2003;18(4):777-81
72. Antonen JA, Hannula PM, Pyhala R, et al. Adequate seroresponse to influenza vaccination in dialysis patients. Nephron 2000;86(1):56-61
73. Mcgrath LJ, Kshirsagar AV, Cole SR, et al. Influenza vaccine effectiveness in patients on hemodialysis: an analysis of a natural experiment. Arch Intern Med 2012;172(7): 548-54
74. Azak A, Huddam B, Kocak G, et al. Antibody response after single H1N1 influenza vaccine in chronic dialysis patients. Ther Apher Dial 2013; 17(1):55-9
75. Baker C, Pickering L, Chilton L, et al. National Center for Immunization and Respiratory Diseases. General recommendations on immunization -recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60(2): 1-64
76. Suga T, Niki H, Niikura M, et al. Influenza antibody titers after vaccination of chronic renal failure patients; before and during hemodialysis, or on continuous ambulatory peritoneal dialysis. Tokai J Exp Clin Med 1990;15(2-3):245-51
77. Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368(20):1888-97
78. Guo H, Liu J, Collins AJ, Foley RN. Pneumonia in incident dialysis patients-the United States Renal Data System. Nephrol Dial Transplant 2008;23(2):680-6
79. Hoyo I, Linares L, Cervera C, et al. Epidemiology of pneumonia in kidney transplantation. Transplant Proc 2010; 42(8):2938-40
80. Gilbertson DT, Guo H, Arneson TJ, Collins AJ. The association of pneumococcal vaccination with hospitalization and mortality in hemodialysis patients. Nephrol Dial Transplant 2011;26(9):2934-9
81. Viasus D, Garcia-Vidal C, Manresa F, et al. Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia. J Infect 2013;66(1):27-33
82. Nikoskelainen J, Koskela M, Forsstrom J, et al. Persistence of antibodies to pneumococcal vaccine in patients with chronic renal failure. Kidney Int 1985; 28(4):672-7
83. Fuchshuber A, Kuhnemund O, Keuth B, et al. Pneumococcal vaccine in children and young adults with chronic renal disease. Nephrol Dial Transplant 1996;11(3):468-73
84. Cosio FG, Giebink GS, Le CT, Schiffman G. Pneumococcal vaccination in patients with chronic renal disease and renal allograft recipients. Kidney Int 1981;20(2): 254-8
85. Landesman SH, Schiffman G. Assessment of the antibody response to pneumococcal vaccine in high-risk populations. Rev Infect Dis 1981;3(Suppl):S184-97
86. Liakou CD, Askiti V, Mitsioni A, et al. Safety, immunogenicity and kinetics of immune response to 7-valent pneumococcal conjugate vaccine in children with idiopathic nephrotic syndrome. Vaccine 2011;29(40):6834-7
87. Vieira S, Baldacci ER, Carneiro-Sampaio M, et al. Evaluation of antibody response to the heptavalent pneumococcal conjugate vaccine in pediatric chronic kidney disease. Pediatr Nephrol 2009;24(1):83-9
88. Barton M, Wasfy S, Dipchand AI, et al. Seven-valent pneumococcal conjugate vaccine in pediatric solid organ transplant recipients: a prospective study of safety and immunogenicity. Pediatr Infect Dis J 2009; 28(8):688-92
89. Mahmoodi M, Aghamohammadi A, Rezaei N, et al. Antibody response to pneumococcal capsular polysaccharide vaccination in patients with chronic kidney disease. Eur Cytokine Netw 2009;20(2): 69-74
90. Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 2010;28(26):4249-59
91. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2012;61(40):816-19
92. Guerin A, Buisson Y, Nutini MT, et al. Response to vaccination against tetanus in chronic haemodialysed patients. Nephrol Dial Transplant 1992;7(4):323-6
93. Kruger S, Muller-Steinhardt M, Kirchner H, Kreft B. A 5-year follow-up on antibody response after diphtheria and tetanus vaccination in hemodialysis patients. Am J Kidney Dis 2001;38(6):1264-70
94. Kruger S, Seyfarth M, Sack K, Kreft B. Defective immune response to tetanus toxoid in hemodialysis patients and its association with diphtheria vaccination. Vaccine 1999;17(9-10):1145-50
95. Kreft B, Fischer A, Kruger S, et al. The impaired immune response to diphtheria vaccination in elderly chronic hemodialysis patients is related to zinc deficiency. Biogerontology 2000;1(1):61-6
96. Atalay B, Ergin F, Teksam M, et al. Spontaneous corynebacterium discitis in a patient with chronic renal failure. Spinal Cord 2004;42(6):378-81
97. Girndt M, Pietsch M, Kohler H. Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure. Am J Kidney Dis 1995;26(3): 454-60
98. Centers for Disease Control. Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory committee (ACIP). MMWR 1991;40(No. RR-10):1-28
99. Sartori AM. A review of the varicella vaccine in immunocompromised individuals. Int J Infect Dis 2004;8(5): 259-70
100. Prelog M, Pohl M, Ermisch B, et al. Demand for evaluation of vaccination antibody titers in children considered for renal transplantation. Pediatr Transplant 2007;11(1):73-6
101. Shinefield H, Black S, Fattom A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002;346(7):491-6
102. Moustafa M, Aronoff GR, Chandran C, et al. Phase IIa study of the immunogenicity and safety of the novel Staphylococcus aureus vaccine V710 in adults with end-stage renal disease receiving hemodialysis. Clin Vaccine Immunol 2012; 19(9):1509-16
103. Anderson AS, Scully IL, Timofeyeva Y, et al. Staphylococcus aureus manganese transport protein C is a highly conserved cell surface protein that elicits protective immunity against S. aureus and Staphylococcus epidermidis. J Infect Dis 2012;205(11):1688-96
104. Hanke T. On DNA vaccines and prolonged expression of immunogens. Eur J Immunol 2006;36(4):806-9.
105. Zi X-Y, Yao Y-C, Zhu H-Y, et al. Long-term persistence of hepatitis B surface antigenand antibody induced by DNA-mediated immunization results in liver and kidney lesions in mice. Eur J Immunol 2006;36(4):875-86
106. Forbes EK, De Cassan SC, Llewellyn D, et al. T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein. PLoS ONE 2012;7(9):e44943
107. Halperin SA, Ward BJ, Dionne M, et al. Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine. Hum Vaccin Immunother 2013;9(7):1438-44